Philadelphia-positive acute lymphoblastic leukemia: Current treatment options

Current Oncology Reports

Volumn 14, Issue 5, 2012, Pages 387-394

  Liu Dumlao, Theresa ^a   Kantarjian, Hagop ^a   Thomas, Deborah A ^a   O'Brien, Susan ^a   Ravandi, Farhad ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

ALL; Allogeneic stem cell transplant; Philadelphia chromosome; Tyrosine kinase inhibitors

Indexed keywords

BOSUTINIB; CYCLOPHOSPHAMIDE; DASATINIB; DEXAMETHASONE; DOXORUBICIN; IMATINIB; NILOTINIB; PONATINIB; PROTEIN TYROSINE KINASE INHIBITOR; REBASTINIB; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; DOSAGE SCHEDULE COMPARISON; DRUG DOSE ESCALATION; DRUG MECHANISM; GENE MUTATION; HUMAN; MINIMAL RESIDUAL DISEASE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHILADELPHIA POSITIVE ACUTE LYMPHOBLASTIC LEUKEMIA; PLEURA EFFUSION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; HUMANS; IMIDAZOLES; NEOPLASM, RESIDUAL; NITRILES; PIPERAZINES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROTEIN KINASE INHIBITORS; PYRIDAZINES; PYRIMIDINES; QUINOLINES; STEM CELL TRANSPLANTATION; THIAZOLES;

EID: 84870549149     PISSN: 15233790     EISSN: 15346269     Source Type: Journal    
DOI: 10.1007/s11912-012-0247-7     Document Type: Article

References (71)

1. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: The cancer and leukemia Group B experience. Blood. 1999;93:3983-93.
2. Faderl S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer. 2003;98:1337-54.
3. Burmeister T, Schwartz S, Bartram CR, Gokbuget N, Hoelzer D, Thiel E. Patients' age and BCR-ABL frequency in adult B-precursorALL: A retrospective analysis from the GMALL study group. Blood. 2008;112:918-9.
4. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973;243:290-3.
5. Secker-Walker LM, Craig JM, Hawkins JM, Hoffbrand AV. Philadelphia positive acute lymphoblastic leukemia in adults: Age distribution, BCR breakpoint and prognostic significance. Leukemia. 1991;5:196-9.
6. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med. 2006;354:166-78.
7. Gleissner B, Gokbuget N, Bartram CR, et al. Leading prognostic relevance of the BCR-ABL translocation in adult acute B-lineage lymphoblastic leukemia: A prospective study of the German Multicenter Trial Group and confirmed polymerase chain reaction analysis. Blood. 2002;99:1536-43.
8. Vitale A, Guarini A, Chiaretti S, Foa R. The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol. 2006;18:652-9.
9. Fielding AK, Rowe JM, Richards SM, et al. Prospective outcome data on 267 unselected adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia confirms superiority of allogeneic transplantation over chemotherapy in the pre-imatinib era: Results from the International ALL Trial MRC UKALLXII/ECOG2993. Blood. 2009;113:4489-96.
10. Ottmann OG, Druker BJ, Sawyers CL, et al. A phase 2 study of imatinib in patients with relapsed or refractory Philadelphia chromosome-positive acute lymphoid leukemias. Blood. 2002;100:1965-71.
11. Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: Review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006;108:28-37.
12. Pfeifer H, Wassmann B, Pavlova A, et al. Kinase domain mutations of BCR-ABL frequently precede imatinib-based therapy and give rise to relapse in patients with de novo Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2007;110:727-34.
13. Hu Y, Liu Y, Pelletier S, et al. Requirement of Src kinases Lyn, Hck and Fgr for BCR-ABL1-induced B-lymphoblastic leukemia but not chronic myeloid leukemia. Nat Genet. 2004;36:453-61.
14. Hu Y, Swerdlow S, Duffy TM, Weinmann R, Lee FY, Li S. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A. 2006;103:16870-5.
15. Lombardo LJ, Lee FY, Chen P, et al. Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino) thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem. 2004;47:6658-61.
16. O'Hare T, Walters DK, Stoffregen EP, et al. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005;65:4500-5.
17. Hiwase DK, Saunders V, Hewett D, et al. Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: Therapeutic implications. Clin Cancer Res. 2008;14:3881-8.
18. Li S. Src-family kinases in the development and therapy of Philadelphia chromosome-positive chronic myeloid leukemia and acute lymphoblastic leukemia. Leuk Lymphoma. 2008;49:19-26.
19. Fielding AK. How I treat Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2010;116:3409-17.
20. SPRYCEL® (dasatinib) [package insert].
21. Talpaz M, Shah NP, Kantarjian H, et al. Dasatinib in imatinibresistant Philadelphia chromosome-positive leukemias. N Engl J Med. 2006;354:2531-41.
22. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: Interim results of a phase 2 study. Blood. 2007;110:2309-15.
23. Porkka K, Martinelli G, Ottmann OG, et al. Dasatinib efficacy in patients with imatinib-resistant/-intolerant Philadelphiachromosome-positive acute lymphoblastic leukemia: 24-month data from START-L. Haematologica. 2008;93 Suppl 1:1(EHA 2008 abstract).
24. Lilly MB, Ottmann OG, Shah NP, et al. Dasatinib 140 mg once daily versus 70 mg twice daily in patients with Ph-positive acute lymphoblastic leukemia who failed imatinib: Results from a phase 3 study. Am J Hematol. 2010;85:164-70.
25. Ravandi F, Kantarjian HM, Cortes J, et al. Combination of the hypercvad regimen with Dasatinib is effective in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) and lymphoid blast phase chronic myeloid leukemia (CML-LB). Blood. 2009;114:806-7.
26. Liu-Dumlao T, O'Brien S, Cortes JE, et al. Combination of the hypercvad regimen with dasatinib in patients with relapsed Philadelphia chromosome (Ph) positive acute lymphoblastic leukemia (ALL) or lymphoid blast phase of chronic myeloid leukemia (CML-LB). ASH Annual Meeting Abstracts. Blood. 2011;118:2578.
27. Foa R, Vitale A, Vignetti M, et al. Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blood. 2011;118:6521-8.
28. Ravandi F, O'Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010;116:2070-7.
29. Lee HJ, Kantarjian HM, Thomas DA, et al. Long-term follow-up of combined hypercvad (hCVAD) regimen with dasatinib (Db) in the front line therapy of patients (pts) with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL). ASH Annual Meeting Abstracts. Blood. 2011;118:1512.
30. Rousselot P, Cayuela JM, Hayette S, et al. Dasatinib (sprycel) and chemotherapy for first-line treatment in elderly patients with de novo Philadelphia positive ALL (EWALL-Ph-01): Analysis of response and resistance. Haematologica. 2009;94 Suppl 2:195(EHA 2009 abstract).
31. Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinibresistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354:2542-51. TASIGNA® (nilotinib) [package Insert].
32. Kim D-Y, Joo YD, Lee J-H, et al. Nilotinib combined with multiagent chemotherapy for adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: Interim results of Korean Adult ALL Working Party Phase 2 Study. ASH Annual Meeting Abstracts. Blood. 2011;118:1517.
33. Giles FJ, Kantarjian HM, le Coutre PD, et al. Nilotinib is effective in imatinib-resistant or-intolerant patients with chronic myeloid leukemia in blastic phase. Leukemia. 2011;26:959-62.
34. Gambacorti-Passerini C, Khoury HJ, Pinczowski H, et al. Clinical activity of bosutinib by mutational status in patients with previously treated Philadelphia chromosome-positive leukemias. ASH Annual Meeting Abstracts. Blood. 2010;116:3434.
35. Cortes JE,KimD-W, Pinilla-Ibarz J, et al. Initial findings fromthe PACE trial: A pivotal phase 2 study of ponatinib in patients with CML and Ph+ ALL resistant or intolerant to dasatinib or nilotinib, or with the T315I mutation. ASH Annual Meeting Abstracts. Blood. 2011;118:109.
36. Cortes JE, Talpaz M, Kantarjian HM, et al. A Phase 1 Study of DCC-2036, a novel oral inhibitor of BCR-ABL kinase, in patients with Philadelphia chromosome positive (Ph+) leukemias including patients with T315I mutation. ASH Annual Meeting Abstracts. Blood. 2011;118:601.
37. Goldstone AH, Richards SM, Lazarus HM, et al. In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: Final results of the International ALL Trial (MRC UKALL XII/ECOG E2993). Blood. 2008;111:1827-33.
38. Arnold R, Massenkeil G, Bornhauser M, et al. Nonmyeloablative stem cell transplantation in adults with high-risk ALL may be effective in early but not in advanced disease. Leukemia. 2002;16:2423-8.
39. Martino R, Giralt S, Caballero M, et al. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: A feasibility study. Haematologica. 2003;88:555-60.
40. Mohty M, Labopin M, Tabrizzi R, et al. Reduced intensity conditioning allogeneic stem cell transplantation for adult patients with acute lymphoblastic leukemia: A retrospective study from the European Group for Blood and Marrow Transplantation. Haematologica. 2008;93:303-6.
41. Stein AS, Palmer JM, O'Donnell MR, et al. Reduced-intensity conditioning followed by peripheral blood stem cell transplantation for adult patients with high-risk acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2009;15:1407-14.
42. Shimoni A, Leiba M, Schleuning M, et al. Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia. Leukemia. 2009;23:190-4.
43. Schultz KR, Bowman WP, Aledo A, et al. Improved Early Event-Free Survival With Imatinib in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. J Clin Oncol. 2009;27:5175-81.
44. Carpenter PA, Snyder DS, Flowers ME, et al. Prophylactic administration of imatinib after hematopoietic cell transplantation for high-risk Philadelphia chromosome-positive leukemia. Blood. 2007;109:2791-3.
45. Pfeifer H, Wassmann B, Bethge WA, et al. Updated long-term results of a randomized comparison of prophylactic and preemptive imatinib following allogeneic stem cell transplantation for Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ALL). ASH Annual Meeting Abstracts. Blood. 2011;118:247.
46. Ravandi F, Thomas DA, O'Brien S, et al. Detection of minimal residual leukemia predicts the outcome of patients with Philadelphia-chromosome positive acute lymphoblastic leukemia treated with tyrosine kinase inhibitors plus chemotherapy. ASH Annual Meeting Abstracts. Blood. 2011;118:1453.
47. Zhou Y, Jorgensen JL, Saliba RM, et al. Pre-transplant minimal residual disease detected by multiparameter flow cytometric analysis predicts for disease relapse in adult patients with acute lymphoblastic leukemia post allogeneic hematopoietic stem cell transplantation. ASH Annual Meeting Abstracts. Blood. 2011;118:3072.
48. Pfeifer H, Cazzaniga G, Spinelli O, et al. International standardization of minimal residual disease assessment for in Philadelphia chromosome positive acute lymphoblastic leukemia (Ph+ ALL) expressing m-BCR-ABL transcripts: Updated results of quality control procedures by the EWALL and ESG-MRD-ALL consortia. ASH Annual Meeting Abstracts. Blood. 2011;118:2535.
49. Ravandi F, Kebriaei P. Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematol Oncol Clin North Am. 2009;23:1043-63.
50. Bloomfield CD, Goldman AI, Alimena G, et al. Chromosomal abnormalities identify high-risk and low-risk patients with acute lymphoblastic leukemia. Blood. 1986;67:415-20.
51. Gotz G, Weh HJ, Walter TA, et al. Clinical and prognostic significance of the Philadelphia chromosome in adult patients with acute lymphoblastic leukemia. Ann Hematol. 1992;64:97-100.
52. Larson RA, Dodge RK, Burns CP, et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: Cancer and leukemia group B study 8811. Blood. 1995;85:2025-37.
53. Cytogenetic abnormalities in adult acute lymphoblastic leukemia: Correlations with hematologic findings outcome. A Collaborative Study of the Group Francais de Cytogenetique Hematologique. Blood. 1996;87:3135-42.
54. Secker-Walker LM, Prentice HG, Durrant J, Richards S, Hall E, Harrison G. Cytogenetics adds independent prognostic information in adults with acute lymphoblastic leukaemia on MRC trial UKALL XA. MRC Adult Leukaemia Working Party. Br J Haematol. 1997;96:601-10.
55. Faderl S, Kantarjian HM, Thomas DA, et al. Outcome of Philadelphia chromosome-positive adult acute lymphoblastic leukemia. Leuk Lymphoma. 2000;36:263-73.
56. Dombret H, Gabert J, Boiron JM, et al. Outcome of treatment in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia-results of the prospective multicenter LALA-94 trial. Blood. 2002;100:2357-66.
57. Arico M, Valsecchi MG, Camitta B, et al. Outcome of treatment in children with Philadelphia chromosome-positive acute lymphoblastic leukemia. N Engl J Med. 2000;342:998-1006.
58. Schrappe M, Arico M, Harbott J, et al. Philadelphia chromosomepositive (Ph+) childhood acute lymphoblastic leukemia: Good initial steroid response allows early prediction of a favorable treatment outcome. Blood. 1998;92:2730-41.
59. Delannoy A, Delabesse E, Lheritier V, et al. Imatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: Results of the GRAALL AFR09 study. Leukemia. 2006;20:1526-32.
60. Delannoy A, Delabesse E, Lheritier V, et al. The long-term outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) in the imatinib era. Haematologica. 2009;Suppl 2:30(EHA 2009 abstract).
61. Yanada M, Takeuchi J, Sugiura I, et al. High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: A phase II study by the Japan Adult Leukemia Study Group. J Clin Oncol. 2006;24:460-6.
62. de Labarthe A, Rousselot P, Huguet-Rigal F, et al. Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: Results of the GRAAPH-2003 study. Blood. 2007;109:1408-13.
63. Ribera JM, Oriol A, Gonzalez M, et al. Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial. Haematologica. 2010;95:87-95.
64. Bassan R, Rossi G, Pogliani EM, et al. Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. J Clin Oncol. 2010;28:3644-52.
65. Wassmann B, Pfeifer H, Goekbuget N, et al. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL). Blood. 2006;108:1469-77.
66. Pfeifer H, Goekbuget N, Volp C, et al. Long-term outcome of 335 adult patients receiving different schedules of imatinib and chemotherapy as front-line treatment for Philadelphia-positive acutelymphoblastic leukemia (Ph+ ALL). ASH Annual Meeting Abstracts. Blood. 2010;116:173.
67. Fielding AK, Buck G, Lazarus HM, et al. Imatinib significantly enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukaemia: Final results of the UKALLXII/ECOG2993 trial. ASH Annual Meeting Abstracts. Blood. 2010;116:169.
68. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004;103:4396-407.
69. Thomas DA, O'Brien SM, Faderl S, et al. Long-term outcome after hyper-CVAD and imatinib (IM) for de novo or minimally treated Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph-ALL). J Clin Oncol. 2010;28 Suppl 15:488s(ASCO 2010 abstract #6506).
70. Foa R, Vitale A, Guarini A, et al. Line Treatment of Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Final results of the GIMEMA LAL1205 Study. ASH Annual Meeting Abstracts. Blood. 2008;112:305.
71. Lee S, Kim D-W, Kim Y-J, et al. First-line dasatinib plus conventional chemotherapy in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL): Interim analysis of the Korean Prospective Phase II Study. ASH Annual Meeting Abstracts. 2011;118:1516.